JP7660135B2 - Ｔｙｋ２阻害剤の結晶形態 - Google Patents

Ｔｙｋ２阻害剤の結晶形態 Download PDF

Info

Publication number
JP7660135B2
JP7660135B2 JP2022559959A JP2022559959A JP7660135B2 JP 7660135 B2 JP7660135 B2 JP 7660135B2 JP 2022559959 A JP2022559959 A JP 2022559959A JP 2022559959 A JP2022559959 A JP 2022559959A JP 7660135 B2 JP7660135 B2 JP 7660135B2
Authority
JP
Japan
Prior art keywords
compound
formula
mixture
crystal
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022559959A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021204762A5 (https=
JP2023521631A (ja
JP2023521631A5 (https=
Inventor
チャールズ リーダー、ジョン
コナー マーシャル、ジェイミー
ミキテューク、ジョン
スコット ノーゼン、ジュリアン
Original Assignee
サリウム リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サリウム リミテッド filed Critical サリウム リミテッド
Publication of JP2023521631A publication Critical patent/JP2023521631A/ja
Publication of JPWO2021204762A5 publication Critical patent/JPWO2021204762A5/ja
Publication of JP2023521631A5 publication Critical patent/JP2023521631A5/ja
Application granted granted Critical
Publication of JP7660135B2 publication Critical patent/JP7660135B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2022559959A 2020-04-07 2021-04-06 Ｔｙｋ２阻害剤の結晶形態 Active JP7660135B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2005114.0 2020-04-07
GBGB2005114.0A GB202005114D0 (en) 2020-04-07 2020-04-07 Crystalline Forms of a Pharmaceutical Compound
PCT/EP2021/058864 WO2021204762A1 (en) 2020-04-07 2021-04-06 Crystalline forms of a tyk2 inhibitor

Publications (4)

Publication Number Publication Date
JP2023521631A JP2023521631A (ja) 2023-05-25
JPWO2021204762A5 JPWO2021204762A5 (https=) 2024-04-01
JP2023521631A5 JP2023521631A5 (https=) 2024-04-01
JP7660135B2 true JP7660135B2 (ja) 2025-04-10

Family

ID=70768933

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022559959A Active JP7660135B2 (ja) 2020-04-07 2021-04-06 Ｔｙｋ２阻害剤の結晶形態

Country Status (12)

Country Link
US (1) US12545652B2 (https=)
EP (1) EP4132649A1 (https=)
JP (1) JP7660135B2 (https=)
KR (1) KR20220164751A (https=)
CN (1) CN115515683B (https=)
AU (1) AU2021253128A1 (https=)
BR (1) BR112022016359A2 (https=)
CA (1) CA3167172A1 (https=)
GB (1) GB202005114D0 (https=)
IL (1) IL296989A (https=)
MX (1) MX2022011593A (https=)
WO (1) WO2021204762A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201816369D0 (en) 2018-10-08 2018-11-28 Sareum Ltd Pharmaceutical compounds
CN118974052A (zh) * 2022-03-25 2024-11-15 武田药品工业株式会社 Tyk2抑制剂的固体形式和使用方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016529264A (ja) 2013-09-03 2016-09-23 サリウム リミテッド 医薬化合物
WO2018073438A1 (en) 2016-10-21 2018-04-26 Sareum Limited Pharmaceutical compounds
JP2022514799A (ja) 2018-10-08 2022-02-15 サリウム リミテッド Ｔｙｋ２キナーゼ阻害剤

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794096A (fr) 1972-08-07 1973-05-16 Lepetit Spa Oxazoles 2,4,5-trisubstitues et leur preparation
GB1497536A (en) 1973-12-17 1978-01-12 Lilly Industries Ltd 2-acylaminooxazoles methods for their preparation and their use
JPH0753716B2 (ja) 1986-07-02 1995-06-07 吉富製薬株式会社 イミダゾ−ルカルボキサミド誘導体
DE19653355A1 (de) 1996-12-20 1998-06-25 Dresden Arzneimittel Neue, antikonvulsiv wirkende Aminoimidazole und Verfahren zu ihrer Herstellung
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
ATE394102T1 (de) 2000-06-28 2008-05-15 Astrazeneca Ab Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
CN100400040C (zh) 2000-10-30 2008-07-09 詹森药业有限公司 三肽酶抑制剂
CA2491895C (en) 2002-07-09 2011-01-18 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
EP1684750B1 (en) 2003-10-23 2010-04-28 AB Science 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
GB0504753D0 (en) 2005-03-08 2005-04-13 Astrazeneca Ab Chemical compounds
KR20080066938A (ko) 2005-10-07 2008-07-17 깃세이 야쿠힌 고교 가부시키가이샤 질소 함유 복소환 화합물 및 그것을 함유하는 의약 조성물
ES2352320T3 (es) 2006-05-12 2011-02-17 Ab Science Nuevo procedimiento para la síntesis de compuestos de 2-aminoxazol.
US20090093452A1 (en) 2006-08-24 2009-04-09 Pfizer Inc. Pyrrole, Thiophene, Furan, Imidazole, Oxazole, and Thiazole Derivatives
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
ES2395581T3 (es) 2007-06-20 2013-02-13 Merck Sharp & Dohme Corp. Inhibidores de quinasas janus
US8278335B2 (en) 2008-04-21 2012-10-02 Merck Sharp & Dohme Corp. Inhibitors of Janus kinases
WO2009155156A1 (en) 2008-06-18 2009-12-23 Merck & Co., Inc. Inhibitors of janus kinases
EP2310384B1 (en) 2008-07-09 2014-04-09 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
EP2166006A1 (en) 2008-09-18 2010-03-24 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
CA2793024A1 (en) 2010-03-17 2011-09-22 F. Hoffmann-La Roche Ag Imidazopyridine compounds, compositions and methods of use
EP2588105A1 (en) 2010-07-01 2013-05-08 Cellzome Limited Triazolopyridines as tyk2 inhibitors
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US20140228349A1 (en) 2011-10-12 2014-08-14 Array Biopharma Inc. 5,7-substituted-imidazo[1,2-c]pyrimidines
DK2634185T3 (en) 2012-03-02 2016-03-21 Sareum Ltd Tyk2 kinase inhibitors
KR101202026B1 (ko) 2012-07-03 2012-11-16 민호현 황토 석부작 제조 방법
MY194668A (en) 2012-11-08 2022-12-12 Bristol Myers Squibb Co Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn() responses
NO2721710T3 (https=) 2014-08-21 2018-03-31

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016529264A (ja) 2013-09-03 2016-09-23 サリウム リミテッド 医薬化合物
WO2018073438A1 (en) 2016-10-21 2018-04-26 Sareum Limited Pharmaceutical compounds
JP2022514799A (ja) 2018-10-08 2022-02-15 サリウム リミテッド Ｔｙｋ２キナーゼ阻害剤

Also Published As

Publication number Publication date
AU2021253128A1 (en) 2022-08-25
JP2023521631A (ja) 2023-05-25
BR112022016359A2 (pt) 2022-10-04
CA3167172A1 (en) 2021-10-14
MX2022011593A (es) 2022-10-18
CN115515683A (zh) 2022-12-23
WO2021204762A1 (en) 2021-10-14
KR20220164751A (ko) 2022-12-13
US12545652B2 (en) 2026-02-10
GB202005114D0 (en) 2020-05-20
US20230159473A1 (en) 2023-05-25
EP4132649A1 (en) 2023-02-15
CN115515683B (zh) 2024-10-25
IL296989A (en) 2022-12-01

Similar Documents

Publication Publication Date Title
US11673870B2 (en) Pharmaceutical compounds
JP6239118B2 (ja) 医薬化合物
JP7660135B2 (ja) Ｔｙｋ２阻害剤の結晶形態
JP7383030B2 (ja) Ｔｙｋ２キナーゼ阻害剤
RU2805932C2 (ru) Фармацевтические соединения
HK40048146B (en) Tyk2 kinase inhibitors
HK40048146A (en) Tyk2 kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250210

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250306

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250331

R150 Certificate of patent or registration of utility model

Ref document number: 7660135

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150